manogepix susceptibility testing of South African , and clinical isolates.

We performed antifungal susceptibility testing of manogepix against the yeast phase of 78 , 2 and 5 isolates using a reference broth microdilution method following Clinical and Laboratory Standards Institute recommendations. All three pathogens had low minimum inhibitory concentrations ranging from <0.0005 to 0.008 mg/L. Manogepix should be investigated in animal models and potentially in future human clinical trials for endemic mycoses.